Goldman Sachs
ANRO icon

Goldman Sachs’s Alto Neuroscience ANRO Stock Holding History

Goldman Sachs’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Sell
104,717
-51,602
-33% -$956K ﹤0.01% 4393
2025
Q4 		$2.78M Buy
156,319
+66,068
+73% +$832K ﹤0.01% 4285
2025
Q3 		$363K Sell
90,251
-75,836
-46% -$251K ﹤0.01% 5667
2025
Q2 		$365K Buy
166,087
+65,713
+65% +$156K ﹤0.01% 5338
2025
Q1 		$217K Sell
100,374
-10,903
-10% -$39K ﹤0.01% 5605
2024
Q4 		$471K Buy
111,277
+65,740
+144% +$410K ﹤0.01% 5282
2024
Q3 		$521K Buy
45,537
+31,382
+222% +$384K ﹤0.01% 5027
2024
Q2 		$151K Buy
+14,155
New +$184K ﹤0.01% 5331

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's ANRO Position: Q1 2026 in Review

Goldman Sachs reduced its Alto Neuroscience (ANRO) stake by 33% in Q1 2026, selling an estimated $956K and leaving 104,717 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4393.

Goldman Sachs first reported a position in ANRO in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.78M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Goldman Sachs held 104,717 shares of Alto Neuroscience worth $2.35M as of Q1 2026.
  • Goldman Sachs sold 51,602 Alto Neuroscience shares in Q1 2026, an estimated $956K.
  • Alto Neuroscience made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4393 holding.
  • Goldman Sachs first reported a position in Alto Neuroscience in Q2 2024 and has held it in 8 quarters since.
  • Goldman Sachs's Alto Neuroscience position peaked at $2.78M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.